Polar Capital Holdings’s Verona Pharma VRNA Stock Holding History

Polar Capital Holdings’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-875,000	Closed	-$82.8M	–	299
2025 Q2	$82.8M	Buy	+875,000	New	+$64.8M	0.43%	63
2021 Q3	–	Sell	-900,000	Closed	-$5.89K	–	375
2021 Q2	$5.89K	Sell	900,000 -100,000	-10%	-$693K	0.03%	265
2021 Q1	$8.36M	Sell	1,000,000 -625,000	-38%	-$5.19M	0.05%	221
2020 Q4	$11.4M	Buy	+1,625,000	New	+$11M	0.07%	201

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Polar Capital Holdings's VRNA Position: Q3 2025 in Review

Polar Capital Holdings sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 875,000 shares — an estimated $82.8M sold.

Polar Capital Holdings first reported a position in VRNA in Q4 2020 and held it in 4 quarters. The position peaked at $82.8M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Polar Capital Holdings reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Polar Capital Holdings sold 875,000 Verona Pharma shares in Q3 2025, an estimated $82.8M.
Polar Capital Holdings first reported a position in Verona Pharma in Q4 2020 and held it in 4 quarters.
Polar Capital Holdings's Verona Pharma position peaked at $82.8M in Q2 2025.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Polar Capital Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.